Brian Tam

Brian is a Director in KPMG’s Healthcare and Life Sciences Strategy Practice. He has over 10 years experience in strategy consulting and market research specializing in growth, pipeline and in-line strategy, as well as commercial due diligence for both strategics and private investors.

Prior to KPMG, Brian was a Vice President at EY-Parthenon where he specialized in the Life Science industry. Brian led numerous strategy and CDD projects focused on helping clients from across Life Sciences, including biopharma., pharma services, diagnostics, and medical devices to identify and pursue market opportunities.

Prior to joining EY-Parthenon, Brian was a Manager at CVS Health where he developed adherence programs and initiatives for the Retail Pharmacy group and an engagement manager at Scientia Advisors / Precision for Medicine where he focused on commercial strategy and growth strategy engagements across the life science industry

Representative Professional and Industry Experience

• Numerous engagements for private equity clients including:
  • Buy side commercial due diligence (CDD) to assess a CDMO that manufactures adeno-associated viral vectors for biopharma companies developing gene therapies
  • Buy side CDD to assess a target that manufactures DNA plasmids for use in cell and gene therapies
  • Sell side diligence for an analytics and marketing company that provides services to biopharma clients to optimize commercial brand strategies to healthcare providers
  • Buy side CDD to assess a contract research organization focused in the preclinical development space
  • Buy side CDD to assess rights to pharmaceutical cardiovascular and diabetes assets in the Chinese market
  • Potential target scan and identification for pharma service companies supporting cell and gene therapy development
  • Buy side CDD to assess a radiopharmaceutical manufacturer of nuclear medicine
  • Buy side CDD to assess a real world evidence target in the dermatology hepatology and immunology space
• Numerous engagements with corporate clients including:
  • Development of a business case for a consumer products company for entry into life sciences, including pharmaceutical and medical device development
  • Sell side diligence of a molecular diagnostics brand focused on pathogen testing and food safety
  • Inorganic growth strategy for midsized biopharma to assess adjacent markets for accretive and pipeline opportunities to opioid addiction therapy to assist client reach short term financial targets and long term viability
  • Competitive strategy development for top 3 brand to blunt competitor product launches by assessing the current and future competitive landscape, various branding and product differentiation scenarios, clinical efficacy, and treatment paradigms
  • Growth strategy development into overseas markets for key prognostic breast cancer test including organic and inorganic growth options, country prioritization